Director/PDMR Shareholding

Summary by AI BETAClose X

Convatec Group Plc has announced share purchases by its Chief Executive Officer, Jonny Mason, who acquired 50,000 ordinary shares at £2.01169 each, and Chief Financial Officer, Fiona Ryder, who purchased 24,993 ordinary shares at £2.00071 each, both transactions occurring on May 26, 2026. These notifications are made by persons discharging managerial responsibilities and are in accordance with market abuse regulations.

Disclaimer*

Convatec Group PLC
27 May 2026
 

27 May 2026

Convatec Group Plc
("Convatec" or "the Company")

Director/PDMR Shareholding 

The Company was notified on 26 May 2026 of the following share purchase transactions in relation to Jonny Mason, Chief Executive Officer and Fiona Ryder, Chief Financial Officer in respect of ordinary shares of 10 pence each in the Company ("Shares"):

Jonny Mason: 50,000 Shares  

Fiona Ryder: 24,993 Shares

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1

 

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

 

Jonny Mason

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer and PDMR

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Convatec Group Plc

b)

 

LEI

 

213800LS272L4FIDOH92

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary share of 10p each in Convatec Group Plc



Identification code

GB00BD3VFW73



b)

 

Nature of the transaction

 

Share purchase

 

c)

Price(s) and volume(s)

 

 

 

 

Price(s)

Volume(s)

£2.01169

50,000

d)

 

Aggregated information




- Aggregated volume

N/A - single transaction



- Price

£2.01169



e)

 

Date of the transaction

 

2026-05-26

f)

 

Place of the transaction

 

XLON

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

 

Fiona Ryder 

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Financial Officer and PDMR

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Convatec Group Plc

b)

 

LEI

 

213800LS272L4FIDOH92

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary share of 10p each in Convatec Group Plc



Identification code

GB00BD3VFW73



b)

 

Nature of the transaction

 

 

Share purchase

c)

Price(s) and volume(s)

 

 

 

 

Price(s)

Volume(s)

£2.00071

24,993

d)

 

Aggregated information




- Aggregated volume

N/A - single transaction



- Price

£2.00071



e)

 

Date of the transaction

 

2026-05-26

f)

 

Place of the transaction

 

XLON

 

Enquiries

James Kerton Company Secretary                                                             
Email: cosec@convatec.com 

Convatec Group Plc's LEI code is 213800LS272L4FIDOH92

Classification: 2.2 Information disclosed under article 19 of the Market Abuse Regulation

About Convatec

 

Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With over 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention, treatment for hard to heal wounds, at-risk skin and ulcerated tissue to supporting debilitating conditions, improved patient outcomes and reduced care costs. Convatec's revenues in 2025 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings